-
Allitinib tosylate
- names:
Allitinib tosylate
- CAS号:
1050500-29-2
MDL Number: - MF(分子式): C31H26ClFN4O5S MW(分子量): 621.08
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|
| 中文别名 | |
| 英文别名 | Allitinib tosylate |
| CAS号 | 1050500-29-2 |
| Inchi | |
| InchiKey | |
| 分子式 Formula | C31H26ClFN4O5S |
| 分子量 Molecular Weight | 621.08 |
| 溶解度Solubility | 生物体外In Vitro:DMSO溶解度50 mg/mL(80.50 mM;Need ultrasonic)H2O< 0.1 mg/mL(insoluble) |
| 性状 | |
| 储藏条件 Storage conditions | 粉末Powder: -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月 |
| 产品说明 | |
| Introduction | Allitinib tosylate (AST-1306 TsOH) is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases. IC50 value: 0.5/3 nM (EGFR/Erb2)[1] Target: EGFR/Erb2;Mutant EGFR T790M/L858R Allitinib functions as an irreversible inhibitor, most likely through covalent interaction with Cys797 and Cys805 in the catalytic domains of EGFR and ErbB2, respectively. Further studies showed that Allitinib inactivated pathways downstream of these receptors and thereby inhibited the proliferation of a panel of cancer cell lines. Allitinib is a potent(pM) and selective inhibitor of EGFR and ErbB4 (IC50 = 500pM and 800 pM, respectively). AST-1306 blocks phosphorylation of EGFR and also prevents downstream pathways. Allitinib also dose-dependently inhibits EGF-induced EGFR phosphorylation in the A549 cancer cell line. |
| Application1 | |
| Application2 | |
| Application3 |
Allitinib tosylate (AST-1306 TsOH) is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases.
IC50 value: 0.5/3 nM (EGFR/Erb2)[1]
Target: EGFR/Erb2;Mutant EGFR T790M/L858R
Allitinib functions as an irreversible inhibitor, most likely through covalent interaction with Cys797 and Cys805 in the catalytic domains of EGFR and ErbB2, respectively. Further studies showed that Allitinib inactivated pathways downstream of these receptors and thereby inhibited the proliferation of a panel of cancer cell lines. Allitinib is a potent(pM) and selective inhibitor of EGFR and ErbB4 (IC50 = 500pM and 800 pM, respectively). AST-1306 blocks phosphorylation of EGFR and also prevents downstream pathways. Allitinib also dose-dependently inhibits EGF-induced EGFR phosphorylation in the A549 cancer cell line.
| 【1】.Xie H, Lin L, Tong L et al. AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS One. 2011;6(7):e21487. |
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


